Potassium Carbonate → 5-(5-chloro-2-thienyl)-3-(1-{[3-(1-pyrrolidinyl)propyl]sulfonyl}-4-piperidinyl)-1H-indole-7-carboxamide
反応式
N1([CH2:6][CH2:7][S:8]([N:11]2[CH2:16][CH2:15][CH:14]([C:17]3[C:25]4[C:20](=[C:21]([C:31]([NH2:33])=[O:32])[CH:22]=[C:23](C5C=CSC=5)[CH:24]=4)[NH:19][CH:18]=3)[CH2:13][CH2:12]2)(=[O:10])=[O:9])CCCC1.[Cl:34][C:35]1[S:39][C:38](B(O)O)=[CH:37][CH:36]=1.C(=O)([O-])[O-].[K+].[K+].O1[CH2:54][CH2:53]OCC1>O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[Cl:34][C:35]1[S:39][C:38]([C:23]2[CH:24]=[C:25]3[C:20](=[C:21]([C:31]([NH2:33])=[O:32])[CH:22]=2)[NH:19][CH:18]=[C:17]3[CH:14]2[CH2:13][CH2:12][N:11]([S:8]([CH2:7][CH2:6][CH2:16][N:11]3[CH2:54][CH2:53][CH2:13][CH2:12]3)(=[O:10])=[O:9])[CH2:16][CH2:15]2)=[CH:37][CH:36]=1参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
The title compound was prepared following the general procedure described in intermediate 16. Thus, 15-bromo-3-(1-{[3-(1-pyrrolidinyl)propyl]sulfonyl}-4-piperidinyl)-1H-indole-7-carboxamide (95 mg, 0.19 mmol) in dioxane (3 mL) and water (1 mL), 5-chloro-2-thienylboronic acid (123 mg, 0.76 mmol), Pd(PPh3)4 (22.2 mg, 10%) and potassium carbonate (211 mg, 1.52 mmol) in dioxane (3.0 mL) and water (1.0 mL) were reacted to form the desired product which was purified by reverse phase HPLC eluting with 10% B to 80% B, where A=H2O (0.1% trifluoroacetic acid) and B=CH3CN (0.1% trifluoroacetic acid) to give the title compound (11 mg, 11%).
後処理
- customThe title compound was prepared
出典と根拠
- ORDレコード
- ord-8d29cd79ba3c4f86a1efb03bb449f4bd
- 出典データセット
- uspto-grants-2010_12
- 特許番号
- US07858796B2
反応ノート
読み込み中…